This week's pod offers a brief review of FGFR inhibitors for cholangiocarcinoma in repsonse to the FDA approval of the latest one, lirafugratinib.
LITESPARK-011 demonstrated improved PFS of lenvantinib + belzutifan vs. cabozantinib in the 2nd-line setting of advanced ccRCC. This led to a recent FDA approval. We look at the toxicity, QOL, and OS data known about this combination regimen.
Download the Learning Oncology Companion: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm
More episodes from "OncoPharm"



Don't miss an episode of “OncoPharm” and subscribe to it in the GetPodcast app.








